AI assistant
Sending…
Salarius Pharmaceuticals, Inc. — Director's Dealing 2017
Jul 27, 2017
35494_dirs_2017-07-27_c757214e-92bf-42f5-a4c2-7cc7615a4786.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2017-07-26
Reporting Person: MacKinnon Roderick (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-07-26 | Stock Option (right to buy) | $4.08 | A | 12000 | Acquired | 2027-07-26 | Common Stock (12000.0) | Direct |
Footnotes
F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017.
More from Salarius Pharmaceuticals, Inc.
Regulatory Filings
2026
May 19
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Declaration of Voting Results & Voting Rights Announcements
2026
Feb 25
Major Shareholding Notification
2026
Feb 17
Proxy Solicitation & Information Statement
2026
Jan 9
Regulatory Filings
2026
Jan 8
Delisting Announcement
2026
Jan 2
Director's Dealing
2026
Jan 2